Skip to main content
Top
Gepubliceerd in:

24-01-2023 | ORIGINAL PAPER

Intensive Mindfulness Meditation Reduces Frequency and Burden of Migraine: An Unblinded Single-Arm Trial

Auteurs: Madhav Goyal, Jennifer A. Haythornthwaite, Sharat Jain, Barbara Lee Peterlin, Megha Mehrotra, David Levine, Jason D. Rosenberg, Mary Minges, David A. Seminowicz, Daniel E. Ford

Gepubliceerd in: Mindfulness | Uitgave 2/2023

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Objectives

Preventing migraine headaches and improving the quality of life for patients with migraine remains a challenge. We hypothesized intensive meditation training would reduce the disease burden of migraine.

Method

An unblinded trial was analyzed as a single cohort exposed to a silent 10-day Vipassana meditation retreat that included 100 hr of sitting meditation. Participants with chronic or episodic migraine were enrolled and followed for 1 year. The primary outcome was a change in mean monthly migraine days at 12 months from baseline. Secondary outcomes included headache frequency and intensity, acute medication use, work days missed, home meditation, sleep quality, general health, quality of life, migraine impact, positive and negative affect, perceived stress, mindfulness, and pain catastrophizing.

Results

Three hundred people were screened and 58 (19%) agreed to participate and enrolled in the intensive meditation training. Forty-six participants with chronic migraine (≥ 15 headaches/month of which ≥ 8 were migraines) and 12 with episodic migraine (< 15 and ≥ 4 migraines/month) attended and 45 (78%) completed the retreat. At 12 months, the average migraine frequency was reduced by 2.7 days (from 16.6 at baseline) per 28 days (95%CI − 4.3, − 1.3) and headaches by 3.4 (20.1 at baseline) per 28 days (− 4.9, − 1.9). Fifty percent responder rate was 29% for migraine. Acute medication use dropped by an average of 2.2 days (− 3.9, − 0.5) per 28 days, and participants reported 2.3 fewer days (− 4.0, − 0.5) on which they reduced their activity due to migraines. The most striking and promising effects were in several secondary outcomes, including migraine-specific quality of life, pain catastrophizing, and perceived stress. The significant improvements observed immediately following the intervention were sustained at 12 months follow-up.

Conclusions

Training in Vipassana meditation via a 10-day retreat may reduce the frequency and burden of migraine.

Preregistration

ClinicalTrials.​gov: NCT00663585.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
go back to reference Al-Hussaini, A., Dorvlo, A. S., Antony, S. X., Chavan, D., Dave, J., Purecha, V., Al-Rahbi, S., & Al-Adawi, S. (2001). Vipassana meditation: A naturalistic, preliminary observation in Muscat. Journal for Scientific Research: Medical Sciences, 3(2), 87–92.PubMedPubMedCentral Al-Hussaini, A., Dorvlo, A. S., Antony, S. X., Chavan, D., Dave, J., Purecha, V., Al-Rahbi, S., & Al-Adawi, S. (2001). Vipassana meditation: A naturalistic, preliminary observation in Muscat. Journal for Scientific Research: Medical Sciences, 3(2), 87–92.PubMedPubMedCentral
go back to reference Diener, H. C., Tfelt-Hansen, P., Dahlof, C., Lainez, M. J., Sandrini, G., Wang, S. J., Neto, W., Vijapurkar, U., Doyle, A., Jacobs, D., MS Group. (2004). Topiramate in migraine prophylaxis–Results from a placebo-controlled trial with propranolol as an active control. Journal of Neurology, 251(8), 943–950. https://doi.org/10.1007/s00415-004-0464-6CrossRefPubMed Diener, H. C., Tfelt-Hansen, P., Dahlof, C., Lainez, M. J., Sandrini, G., Wang, S. J., Neto, W., Vijapurkar, U., Doyle, A., Jacobs, D., MS Group. (2004). Topiramate in migraine prophylaxis–Results from a placebo-controlled trial with propranolol as an active control. Journal of Neurology, 251(8), 943–950. https://​doi.​org/​10.​1007/​s00415-004-0464-6CrossRefPubMed
go back to reference Dodick, D. W., Silberstein, S. D., Bigal, M. E., Yeung, P. P., Goadsby, P. J., Blankenbiller, T., Grozinski-Wolff, M., Yang, R., Ma, Y., & Aycardi, E. (2018). Effect of fremanezumab compared with placebo for prevention of episodic migraine: A randomized clinical trial. JAMA, 319(19), 1999–2008. https://doi.org/10.1001/jama.2018.4853CrossRefPubMed Dodick, D. W., Silberstein, S. D., Bigal, M. E., Yeung, P. P., Goadsby, P. J., Blankenbiller, T., Grozinski-Wolff, M., Yang, R., Ma, Y., & Aycardi, E. (2018). Effect of fremanezumab compared with placebo for prevention of episodic migraine: A randomized clinical trial. JAMA, 319(19), 1999–2008. https://​doi.​org/​10.​1001/​jama.​2018.​4853CrossRefPubMed
go back to reference Goslin, R. E., Gray, R. N., McCrory, D. C., Penzien, D., Rains, J., & Hasselblad, V. (1999). Behavioral and physical treatments for migraine headache (National Technical Information Service (NTIS) Accession No. PB99–127946). Department of Health and Human Services. http://www.ncbi.nlm.nih.gov/pubmed/20734517. Accessed 28 June 2022 Goslin, R. E., Gray, R. N., McCrory, D. C., Penzien, D., Rains, J., & Hasselblad, V. (1999). Behavioral and physical treatments for migraine headache (National Technical Information Service (NTIS) Accession No. PB99–127946). Department of Health and Human Services. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​20734517. Accessed 28 June 2022
go back to reference Grazzi, L., Sansone, E., Raggi, A., D’Amico, D., De Giorgio, A., Leonardi, M., De Torres, L., Salgado-Garcia, F., & Andrasik, F. (2017). Mindfulness and pharmacological prophylaxis after withdrawal from medication overuse in patients with chronic migraine: An effectiveness trial with a one-year follow-up. Journal of Headache and Pain, 18(1), 15. https://doi.org/10.1186/s10194-017-0728-zCrossRefPubMedPubMedCentral Grazzi, L., Sansone, E., Raggi, A., D’Amico, D., De Giorgio, A., Leonardi, M., De Torres, L., Salgado-Garcia, F., & Andrasik, F. (2017). Mindfulness and pharmacological prophylaxis after withdrawal from medication overuse in patients with chronic migraine: An effectiveness trial with a one-year follow-up. Journal of Headache and Pain, 18(1), 15. https://​doi.​org/​10.​1186/​s10194-017-0728-zCrossRefPubMedPubMedCentral
go back to reference Hart, W. (2005). The art of living: Vipassana meditation as taught by S.N. Goenka. Vipassana Research Institute. Hart, W. (2005). The art of living: Vipassana meditation as taught by S.N. Goenka. Vipassana Research Institute.
go back to reference Karam, F., Berard, A., Sheehy, O., Huneau, M. C., Briggs, G., Chambers, C., Einarson, A., Johnson, D., Kao, K., Koren, G., Martin, B., Polifka, J. E., Riordan, S. H., Roth, M., Lavigne, S. V., Wolfe, L., & Committee, O. R. (2012). Reliability and validity of the 4-item perceived stress scale among pregnant women: Results from the OTIS antidepressants study. Research in Nursing and Health, 35(4), 363–375. https://doi.org/10.1002/nur.21482CrossRefPubMed Karam, F., Berard, A., Sheehy, O., Huneau, M. C., Briggs, G., Chambers, C., Einarson, A., Johnson, D., Kao, K., Koren, G., Martin, B., Polifka, J. E., Riordan, S. H., Roth, M., Lavigne, S. V., Wolfe, L., & Committee, O. R. (2012). Reliability and validity of the 4-item perceived stress scale among pregnant women: Results from the OTIS antidepressants study. Research in Nursing and Health, 35(4), 363–375. https://​doi.​org/​10.​1002/​nur.​21482CrossRefPubMed
go back to reference Penzien, D. B., Andrasik, F., Freidenberg, B. M., Houle, T. T., Lake, A. E., 3rd., Lipchik, G. L., Holroyd, K. A., Lipton, R. B., McCrory, D. C., Nash, J. M., Nicholson, R. A., Powers, S. W., Rains, J. C., & Wittrock, D. A. (2005). Guidelines for trials of behavioral treatments for recurrent headache, first edition: American Headache Society Behavioral Clinical Trials Workgroup. Headache, 45(Suppl 2), S110–S132. https://doi.org/10.1111/j.1526-4610.2005.4502004.x Penzien, D. B., Andrasik, F., Freidenberg, B. M., Houle, T. T., Lake, A. E., 3rd., Lipchik, G. L., Holroyd, K. A., Lipton, R. B., McCrory, D. C., Nash, J. M., Nicholson, R. A., Powers, S. W., Rains, J. C., & Wittrock, D. A. (2005). Guidelines for trials of behavioral treatments for recurrent headache, first edition: American Headache Society Behavioral Clinical Trials Workgroup. Headache, 45(Suppl 2), S110–S132. https://​doi.​org/​10.​1111/​j.​1526-4610.​2005.​4502004.​x
go back to reference Reuter, U., Goadsby, P. J., Lanteri-Minet, M., Wen, S., Hours-Zesiger, P., Ferrari, M. D., & Klatt, J. (2018). Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: A randomised, double-blind, placebo-controlled, phase 3b study. Lancet, 392(10161), 2280–2287. https://doi.org/10.1016/S0140-6736(18)32534-0CrossRefPubMed Reuter, U., Goadsby, P. J., Lanteri-Minet, M., Wen, S., Hours-Zesiger, P., Ferrari, M. D., & Klatt, J. (2018). Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: A randomised, double-blind, placebo-controlled, phase 3b study. Lancet, 392(10161), 2280–2287. https://​doi.​org/​10.​1016/​S0140-6736(18)32534-0CrossRefPubMed
go back to reference Ronel, N., Frid, N., & Timor, U. (2013). The practice of positive criminology: A Vipassana course in prison. International Journal of Offender Therapy and Comparative Criminology, 57(2), 133–153.CrossRefPubMed Ronel, N., Frid, N., & Timor, U. (2013). The practice of positive criminology: A Vipassana course in prison. International Journal of Offender Therapy and Comparative Criminology, 57(2), 133–153.CrossRefPubMed
go back to reference Seminowicz, D. A., Burrowes, S. A. B., Kearson, A., Zhang, J., Krimmel, S. R., Samawi, L., Furman, A. J., Keaser, M. L., Gould, N. F., Magyari, T., White, L., Goloubeva, O., Goyal, M., Peterlin, B. L., & Haythornthwaite, J. A. (2020). Enhanced mindfulness-based stress reduction in episodic migraine: A randomized clinical trial with magnetic resonance imaging outcomes. Pain, 161(8), 1837–1846. https://doi.org/10.1097/j.pain.0000000000001860CrossRefPubMedPubMedCentral Seminowicz, D. A., Burrowes, S. A. B., Kearson, A., Zhang, J., Krimmel, S. R., Samawi, L., Furman, A. J., Keaser, M. L., Gould, N. F., Magyari, T., White, L., Goloubeva, O., Goyal, M., Peterlin, B. L., & Haythornthwaite, J. A. (2020). Enhanced mindfulness-based stress reduction in episodic migraine: A randomized clinical trial with magnetic resonance imaging outcomes. Pain, 161(8), 1837–1846. https://​doi.​org/​10.​1097/​j.​pain.​0000000000001860​CrossRefPubMedPubMedCentral
go back to reference Seng, E. K., Singer, A. B., Metts, C., Grinberg, A. S., Patel, Z. S., Marzouk, M., Rosenberg, L., Day, M., Minen, M. T., Lipton, R. B., & Buse, D. C. (2019). Does mindfulness-based cognitive therapy for migraine reduce migraine-related disability in people with episodic and chronic migraine? A phase 2b pilot randomized clinical trial. Headache, 59(9), 1448–1467. https://doi.org/10.1111/head.13657CrossRefPubMedPubMedCentral Seng, E. K., Singer, A. B., Metts, C., Grinberg, A. S., Patel, Z. S., Marzouk, M., Rosenberg, L., Day, M., Minen, M. T., Lipton, R. B., & Buse, D. C. (2019). Does mindfulness-based cognitive therapy for migraine reduce migraine-related disability in people with episodic and chronic migraine? A phase 2b pilot randomized clinical trial. Headache, 59(9), 1448–1467. https://​doi.​org/​10.​1111/​head.​13657CrossRefPubMedPubMedCentral
go back to reference Silberstein, S. D., Lipton, R. B., Dodick, D. W., Freitag, F. G., Ramadan, N., Mathew, N., Brandes, J. L., Bigal, M., Saper, J., Ascher, S., Jordan, D. M., Greenberg, S. J., Hulihan, J., Topiramate Chronic Migraine Study Group. (2007). Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial. Headache, 47(2), 170–180. https://doi.org/10.1111/j.1526-4610.2006.00684.xCrossRefPubMed Silberstein, S. D., Lipton, R. B., Dodick, D. W., Freitag, F. G., Ramadan, N., Mathew, N., Brandes, J. L., Bigal, M., Saper, J., Ascher, S., Jordan, D. M., Greenberg, S. J., Hulihan, J., Topiramate Chronic Migraine Study Group. (2007). Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial. Headache, 47(2), 170–180. https://​doi.​org/​10.​1111/​j.​1526-4610.​2006.​00684.​xCrossRefPubMed
go back to reference Silberstein, S. D., Dodick, D. W., Bigal, M. E., Yeung, P. P., Goadsby, P. J., Blankenbiller, T., Grozinski-Wolff, M., Yang, R., Ma, Y., & Aycardi, E. (2017). Fremanezumab for the preventive treatment of chronic migraine. New England Journal of Medicine, 377(22), 2113–2122. https://doi.org/10.1056/NEJMoa1709038CrossRefPubMed Silberstein, S. D., Dodick, D. W., Bigal, M. E., Yeung, P. P., Goadsby, P. J., Blankenbiller, T., Grozinski-Wolff, M., Yang, R., Ma, Y., & Aycardi, E. (2017). Fremanezumab for the preventive treatment of chronic migraine. New England Journal of Medicine, 377(22), 2113–2122. https://​doi.​org/​10.​1056/​NEJMoa1709038CrossRefPubMed
go back to reference Simshauser, K., Luking, M., Kaube, H., Schultz, C., & Schmidt, S. (2020). Is Mindfulness-Based Stress Reduction a promising and feasible intervention for patients suffering from migraine? A randomized controlled pilot trial. Complementary Medicine Research, 27(1), 19–30. https://doi.org/10.1159/000501425CrossRefPubMed Simshauser, K., Luking, M., Kaube, H., Schultz, C., & Schmidt, S. (2020). Is Mindfulness-Based Stress Reduction a promising and feasible intervention for patients suffering from migraine? A randomized controlled pilot trial. Complementary Medicine Research, 27(1), 19–30. https://​doi.​org/​10.​1159/​000501425CrossRefPubMed
go back to reference Speck, R. M., Yu, R., Ford, J. H., Ayer, D. W., Bhandari, R., & Wyrwich, K. W. (2021). Psychometric validation and meaningful within-patient change of the Migraine-Specific Quality of Life questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine. Headache, 61(3), 511–526. https://doi.org/10.1111/head.14031CrossRefPubMedPubMedCentral Speck, R. M., Yu, R., Ford, J. H., Ayer, D. W., Bhandari, R., & Wyrwich, K. W. (2021). Psychometric validation and meaningful within-patient change of the Migraine-Specific Quality of Life questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine. Headache, 61(3), 511–526. https://​doi.​org/​10.​1111/​head.​14031CrossRefPubMedPubMedCentral
go back to reference Tepper, S., Ashina, M., Reuter, U., Brandes, J. L., Dolezil, D., Silberstein, S., Winner, P., Leonardi, D., Mikol, D., & Lenz, R. (2017). Safety and efficacy of erenumab for preventive treatment of chronic migraine: A randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology, 16(6), 425–434. https://doi.org/10.1016/S1474-4422(17)30083-2CrossRefPubMed Tepper, S., Ashina, M., Reuter, U., Brandes, J. L., Dolezil, D., Silberstein, S., Winner, P., Leonardi, D., Mikol, D., & Lenz, R. (2017). Safety and efficacy of erenumab for preventive treatment of chronic migraine: A randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology, 16(6), 425–434. https://​doi.​org/​10.​1016/​S1474-4422(17)30083-2CrossRefPubMed
Metagegevens
Titel
Intensive Mindfulness Meditation Reduces Frequency and Burden of Migraine: An Unblinded Single-Arm Trial
Auteurs
Madhav Goyal
Jennifer A. Haythornthwaite
Sharat Jain
Barbara Lee Peterlin
Megha Mehrotra
David Levine
Jason D. Rosenberg
Mary Minges
David A. Seminowicz
Daniel E. Ford
Publicatiedatum
24-01-2023
Uitgeverij
Springer US
Gepubliceerd in
Mindfulness / Uitgave 2/2023
Print ISSN: 1868-8527
Elektronisch ISSN: 1868-8535
DOI
https://doi.org/10.1007/s12671-023-02073-z

Andere artikelen Uitgave 2/2023

Mindfulness 2/2023 Naar de uitgave